SF
IART icon

Scott Ferguson’s Integra LifeSciences IART Stock Holding History

Scott Ferguson’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,430,000
Closed -$44.2M – 17
2024
Q3 		$44.2M Buy
+2,430,000
New +$56.3M 2.32% 14

Other funds holding IART

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Scott Ferguson's IART Position: Q4 2024 in Review

Scott Ferguson sold out of Integra LifeSciences (IART) in Q4 2024, closing a stake of 2,430,000 shares — an estimated $44.2M sold.

Scott Ferguson first reported a position in IART in Q3 2024 and held it in 1 quarter. The position peaked at $44.2M in Q3 2024. 223 funds tracked by Wall St. Rank hold IART as of Q4 2024.

  • Scott Ferguson reported no remaining Integra LifeSciences position as of Q4 2024 after selling out during the quarter.
  • Scott Ferguson sold 2,430,000 Integra LifeSciences shares in Q4 2024, an estimated $44.2M.
  • Scott Ferguson first reported a position in Integra LifeSciences in Q3 2024 and held it in 1 quarter.
  • Scott Ferguson's Integra LifeSciences position peaked at $44.2M in Q3 2024.
  • 223 funds tracked by Wall St. Rank held Integra LifeSciences as of Q4 2024.

Based on Sachem Head Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.